Poltreg S.A. is a biotechnology company that engages in the development of innovative cell therapies. The company focuses on creating therapeutic solutions for autoimmune diseases through the use of regulatory T cells (Tregs). These therapies harness the body's immune system to promote immune tolerance, potentially leading to more effective and safer treatment options compared to traditional methods. Poltreg S.A.'s work is primarily targeted at transforming the way autoimmune diseases like Type 1 diabetes and multiple sclerosis are managed, providing a beacon of hope for patients seeking alternatives to standard treatments. The company's research and development efforts place it at the forefront of the biotech industry in its niche field, contributing to advancements in personalized medicine and regenerative therapies. As a player in the growing biotechnology sector, Poltreg S.A. is part of the broader push towards innovative healthcare solutions that aim to improve patient outcomes through scientific breakthroughs.